Eli Lilly shares hit new highs after a regulatory victory in China. This is a big problem
Every weekday, the CNBC Investing Club with Jim Cramer hosts a “Morning Meeting” livestream at 10:20 a.m. ET. Here's a…
Jim Cramer
Danaher shows how holding a good company's troubled stock can pay off
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
No Surprise Amazon Stock Down After Cloud CEO Shakeup
Every weekday, the CNBC Investing Club with Jim Cramer hosts a “Morning Meeting” livestream at 10:20 a.m. ET. Here's a…
Unjustified drop after GEHC results is a buying opportunity
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Eli Lilly (LLY) Says It Can Overcome the Problem of Too Much Demand for High Quality
Eli Lilly's improved guidance stole the show on Tuesday, offsetting mixed first-quarter results and sending shares up nearly 6%. The…
The promise of Eli Lilly's weight-loss drug for sleep apnea adds reasons to own it
Eli Lilly's weight-loss drug Zepbound showed promise as a treatment for sleep apnea, giving investors more confidence to continue owning…
We're buying more shares of this healthcare company amid an overblown sell-off
Shortly after the opening bell, we will purchase 140 shares of Abbott Laboratories at approximately $112. Following the deal, Jim…
Nvidia tramples the bears. Jim Cramer on struggling stocks Starbucks and Abbott
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Jim Cramer defends Elon Musk's use of ketamine for depression
CNBC's Jim Cramer said Tuesday that Elon Musk's revelation that he takes prescription ketamine for depression was brave and “saved…
Disney scores a victory in the Nelson Peltz board fight. 2 other portfolio stocks recover
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…